1.
Journal of the Neurological Sciences
; 429:N.PAG-N.PAG, 2021.
Artículo
en Inglés
| Academic Search Complete | ID: covidwho-1461439
2.
Neurol Sci
; 42(10): 4373-4375, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1384481
3.
Neurol Sci
; 42(10): 3969-3971, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1321759
Asunto(s)
COVID-19 , Esclerosis Múltiple , Depresión , Humanos , Esclerosis Múltiple/epidemiología , Pandemias , SARS-CoV-2
4.
J Neurol
; 268(11): 3975-3979, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1182249
RESUMEN
During the COVID-19 pandemic, concerns raised regarding the use of immunosuppressants in multiple sclerosis, even if current data do not support an increased risk of infection. Although fingolimod can be temporarily suspended during COVID-19, the benefit-risk balance of suspension can be challenging. Till now, no adverse events have been described after the resumption of fingolimod, following a previous discontinuation. We report the occurrence of atrioventricular block following fingolimod restart. Fingolimod acts on sphingosine-1-phosphate-axis, a pathway that is altered with COVID-19 and hypoxic conditions. Herein we discuss how these metabolic changes may have influenced fingolimod pharmacology leading to a cardiac event.